Katarfluid Adulti

Carbocisteine, the active ingredient in Katarfluid Adulti, is a mucolytic presented as an oral formulation for oral use. It reduces the viscosity of respiratory mucus and is employed in the management of chronic bronchitis, COPD, asthma with mucus hypersecretion, and productive upper respiratory infections in adult patients.

GNH USA supplies Katarfluid Adulti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for respiratory care products across global markets.

Carbocisteine is a mucolytic that acts on respiratory secretions to improve clearance in several chronic and acute conditions.

- Chronic bronchitis: reduces mucus thickness and facilitates expectoration, helping to relieve cough and improve airflow. - Chronic obstructive pulmonary disease (COPD): thins bronchial secretions, aiding sputum clearance and reducing exacerbation frequency. - Asthma with mucus hypersecretion: decreases mucus viscosity, supporting better airway patency during attacks. - Upper respiratory tract infections with productive cough: promotes clearance of sputum, easing cough and speeding recovery.

Carbocisteine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, usually transient. - Abdominal pain: discomfort in the stomach region. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Hypersensitivity reactions: including anaphylaxis, requiring immediate medical attention. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Neutropenia or eosinophilia: abnormal blood counts. - Bronchospasm: worsening of breathing difficulty.

Before using Katarfluid Adulti, consider the following precautions. - Dose adjustment: assess renal function and adjust dose in patients with renal impairment. - Hypersensitivity: avoid in individuals with known allergy to carbocisteine or related compounds. - Peptic ulcer disease: use with caution as mucolytics may irritate the gastrointestinal tract. - Liver monitoring: periodic liver function tests are advisable during prolonged therapy. - Pregnancy and lactation: safety not established; consult a healthcare professional before use. - Store at room temperature: keep in the original container, protect from moisture and light.

Carbocisteine may interact with other medicines; review the following.

Major Interactions (Avoid): - Cough suppressants (e.g., codeine): may counteract the expectorant effect of carbocisteine. - Anticholinergic agents: can diminish mucociliary clearance, reducing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: carbocisteine may potentiate anticoagulant effect, requiring INR monitoring. - Theophylline: possible alteration of plasma concentrations, necessitating level checks. - ACE inhibitors: may increase cough frequency, potentially complicating assessment of therapeutic benefit.